-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Barchart·09/15/2026 06:30:00
Listen to the news

Statistically significant benefits observed in bezisterim-treated Long COVID patients 
in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.